AICAR Research Guide: The AMPK Activator Compound

AICAR is a laboratory research compound best known as an activator of AMP-activated protein kinase (AMPK), the enzyme cells use to sense and respond to low energy. Chemically, AICAR is 5-aminoimidazole-4-carboxamide ribonucleotide — also called AICA ribonucleotide or ZMP — an adenosine analog and a natural intermediate in the de novo purine biosynthesis pathway. Inside cells, its riboside form, acadesine, is phosphorylated to AICAR, and AICAR mimics the effect of adenosine monophosphate (AMP) on AMPK, switching on the same energy-conserving program that exercise and fasting trigger. Researchers study AICAR to probe how AMPK signaling controls glucose uptake, fatty acid oxidation, and mitochondrial biogenesis in cell and animal models, which is why the compound became famous in the scientific press as a candidate "exercise mimetic."

What Is AICAR?

A few identity points matter for anyone reading the literature, because two names are often used interchangeably for two different molecules:

• AICAR / ZMP: the ribonucleotide — 5-aminoimidazole-4-carboxamide ribonucleotide. This is the molecule that actually activates AMPK, and it is also a normal metabolic intermediate: in purine biosynthesis, ZMP is converted onward toward IMP.
• Acadesine: the riboside (AICA riboside), formula C9H14N4O5, molecular weight approximately 258.2 Da. Acadesine crosses cell membranes, and once inside the cell the enzyme adenosine kinase phosphorylates it to ZMP. Most cell-culture and animal research described as "AICAR treatment" in fact administers acadesine and relies on this intracellular conversion.
• Class: nucleoside/nucleotide analog; AMPK activator; in sports regulation, classified as a metabolic modulator.
• Status: a research compound. It was investigated as a drug candidate but never approved as a medicine anywhere.

The distinction is more than pedantry. A data sheet that says AICAR and a vial that contains acadesine refer to precursor and product of the same intracellular step, and a laboratory designing an experiment — or checking a certificate of analysis — needs to know which of the two it is actually holding.

Background: From Heart Surgery Candidate to Exercise-Mimetic Fame

AICAR entered research through cardiology, not metabolism. Acadesine was developed as an "adenosine-regulating agent": by raising local adenosine availability in ischemic tissue, it was intended to protect the heart during episodes of reduced blood flow. Through the 1990s and 2000s it was studied in cardiac surgery and heart-attack settings, culminating in a large Phase III trial in patients undergoing coronary artery bypass grafting. That trial was stopped early after interim analysis showed it was unlikely to demonstrate the intended benefit, and the drug-development program ended without an approved product.

The compound's second, larger fame came from a different direction. In 2008, researchers at the Salk Institute reported in the journal Cell that sedentary mice given AICAR for several weeks ran substantially farther in endurance tests than untreated sedentary mice, and that the compound activated genes associated with exercise adaptation in muscle. Newspapers summarized the finding as "exercise in a pill," and AICAR became the best-known pharmacological probe of the idea that the cellular benefits of exercise are switched on by energy-sensing pathways — above all, by AMPK. One regulatory consequence followed quickly: because of its performance-related mechanism, AICAR is prohibited in competitive sport and appears on the World Anti-Doping Agency (WADA) Prohibited List under metabolic modulators.

Mechanism of Action: Mimicking AMP at AMPK

AMPK is a heterotrimeric enzyme — catalytic α, scaffolding β, and regulatory γ subunits — that functions as the cell's fuel gauge. When energy runs low, the AMP-to-ATP ratio rises, AMP binds the γ subunit, and AMPK switches on. Active AMPK then works to restore energy balance: it promotes ATP-producing processes such as glucose uptake and fatty acid oxidation, and it suppresses ATP-consuming processes such as fatty acid and protein synthesis.

AICAR exploits the gauge rather than the fuel supply. ZMP is structurally similar enough to AMP that it binds the same regulatory sites on the AMPK γ subunit. The result, established in the foundational biochemical literature, is that ZMP both allosterically activates AMPK and promotes its activating phosphorylation at threonine 172 by the upstream kinase LKB1, while protecting that phosphate from removal. In practical terms for the laboratory, acadesine gives researchers a pharmacological way to turn AMPK on in cultured cells and animal tissues without changing the cells' actual energy state — no starvation, no exercise, no mitochondrial poison required. Downstream readouts reported in the literature include phosphorylation of acetyl-CoA carboxylase (ACC), translocation of the glucose transporter GLUT4 to the cell membrane in muscle models, and induction of PGC-1α, a transcriptional coactivator associated with mitochondrial biogenesis.

What Researchers Study AICAR For

Exercise metabolism and endurance models

The most cited research area follows from the 2008 Cell study: published studies examined whether pharmacological AMPK activation could reproduce, in sedentary animals, cellular adaptations normally produced by endurance training. Subsequent work has used AICAR to dissect which parts of the exercise response — oxidative enzyme expression, mitochondrial content, substrate selection — are AMPK-dependent and which require other signals that a single compound does not reproduce.

Metabolic disease models

Because AMPK activation increases glucose uptake and fatty acid oxidation in experimental systems, published studies examined AICAR in rodent models of insulin resistance and type 2 diabetes, where researchers measured effects on glucose handling, lipid accumulation, and insulin signaling in muscle, liver, and adipose tissue. These are preclinical model studies: they are used to map pathway behavior, and their results are part of why AMPK remains a heavily studied drug target even though AICAR itself is not a medicine.

Cancer cell metabolism

AMPK sits at a crossroads of growth signaling — it restrains the mTOR pathway that many tumors depend on — so published studies examined AICAR in cancer cell lines, including prostate, breast, and blood-cancer models, measuring effects on proliferation, cell-cycle progression, and survival pathways in vitro. This literature is cell-based and mechanistic; it uses AICAR as a pathway probe, not as a treatment candidate.

Cardiac and ischemic research

The compound's original field remains an active one. Published studies examined AICAR and acadesine in models of ischemia-reperfusion injury, where the questions concern adenosine signaling, energy preservation in oxygen-starved tissue, and the timing of protection around an ischemic event.

Aging and longevity models

Because AMPK activity and PGC-1α-driven mitochondrial maintenance are recurring themes in aging biology, published studies examined AICAR in aging-related models, including work on muscle maintenance and metabolic flexibility in older animals. As with the other areas above, the published record is preclinical and exploratory.

How AICAR Differs From Related Compounds

AICAR is frequently grouped with other "exercise mimetic" or metabolic research compounds, but the mechanisms are distinct. Metformin, the most widely studied AMPK-related drug, activates AMPK indirectly — largely by mildly inhibiting mitochondrial complex I, which changes the cell's AMP-to-ATP ratio; AICAR bypasses that step and mimics AMP directly at the enzyme. GW501516, the compound studied alongside AICAR in the 2008 Cell paper, works through an entirely different target, the nuclear receptor PPARδ, and is not an AMPK activator. And AICAR should not be confused with peptides: it is a small-molecule nucleoside analog, not an amino-acid chain, so it sits in a different reagent class from the peptide compounds that make up most of a research catalog. What the compounds in this space share is only the research question — how energy-sensing pathways regulate metabolism — not a mechanism, a structure, or an evidence base.

Frequently Asked Questions

What does AICAR stand for?

AICAR stands for 5-aminoimidazole-4-carboxamide ribonucleotide. It is also called AICA ribonucleotide or ZMP, and it occurs naturally as an intermediate in the de novo synthesis of purines.

Is acadesine the same thing as AICAR?

Not exactly. Acadesine is the riboside precursor; cells take it up and phosphorylate it to AICAR (ZMP), which is the molecule that activates AMPK. Most research papers use "AICAR" for the treatment even when acadesine is what was administered.

Why is AICAR called an exercise mimetic?

Because a widely reported 2008 study in Cell found that sedentary mice treated with AICAR showed increased endurance and exercise-like gene activation in muscle. The term describes a research concept — activating exercise-associated pathways pharmacologically — not an approved use.

Is AICAR a peptide?

No. AICAR is a small molecule, an analog of the nucleoside adenosine and the nucleotide AMP. It contains no amino-acid chain, which distinguishes it from research peptides.

Is AICAR approved or legal in sport?

AICAR is not an approved medicine in any country; its drug-development program ended after a large Phase III trial was stopped early. In sport, it is prohibited at all times under the WADA Prohibited List as a metabolic modulator.

A Note on Research Use and Verification

AICAR is supplied and used strictly as a laboratory research compound, and the standards that apply to any research reagent apply to it: identity and purity should be verified, not assumed — especially given the acadesine/AICAR naming overlap, where confirming which molecule is in the vial is itself part of quality control. NUPEPS PEPTIDES supplies laboratory research compounds with published certificates of analysis, with purity verified by HPLC and third-party laboratory reports available on the site's COAs page (nupeps.com/coas), so researchers can check the analytical record behind a product before it reaches the bench.